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1. Introduction 
Recent advances in reperfusion strategies have dramatically reduced early mortality after 
acute myocardial infarction (AMI), but as a result there is a higher incidence of heart failure 
among survivors. Optimal medical therapy and device implantation can improve the 
prognosis and the quality of life of these patients. Nevertheless, mortality and 
rehospitalization rates are still high and entail an overwhelming cost. 
The field of cardiac cell therapy has emerged as a new alternative in this situation, and has 
made rapid progress. Its final goal is to repair the damaged myocardium and to restore 
cardiac function. Nevertheless, this goal is hindered by the massive loss of cardiomyocytes 
after an AMI (in the order of 1 billion cells) and because ischemic myocardium loses cellular 
and extracellular signals which guide stem cells to the cardiac lineage or to the secretion of 
paracrine factors (Wollert & Drexler, 2010).  
Studies evaluating this new approach during the last 15 years have overall succeeded to a 
greater or lesser extent, and evidence available so far is encouraging. Phase I and II 
randomized clinical trials (RCT) indicate that cell therapy is a safe treatment which can 
improve cardiac function after AMI and in the chronic phase of coronary artery disease 
(CAD). Trial results are not uniform, however, probably due 1) to a lack of standardization 
of cell isolation and delivery procedures, 2) to the absence of a universally accepted 
nomenclature, and 3) to the large number of stem cell types under investigation in different 
clinical settings. Nevertheless, these inconsistencies can be avoided or reduced if classical 
scientific methodology is followed. Although considered a relatively new field of research, 
stem cell experimentation must invariably walk on the path of the scientific method. Since 
Aristotle´s time, scientific method has been used as a way to ask and answer scientific 
questions by making observations and doing experiments. It includes a series of steps, i.e. 1) 
asking a question, 2) doing background research, 3) constructing a hypothesis, 4) testing the 
hypothesis by doing an experiment, 5) analyzing the data and drawing a conclusion, and 6) 
communicating the results. 
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In the case of stem cell therapy, RCT started questioning if there was a possibility of 
repairing the heart after different types of tissular damage. Background evidence has 
already demonstrated that this possibility exists through stem cell administration in several 
preclinical models of cardiomyopathy. Thus, the key points in the design of present and 
future RCT in humans are 1) to formulate an adequate hypothesis, 2) to select the ideal 
population, cell type and delivery method and 3) to develop a correct and precise protocol. 
These decisions must be made in the light of previous evidence and with a translational 
mentality, in which experimental/preclinical data should help to design new RCT. 
Inversely, results of human studies should transfer new questions and hypothesis to the 
laboratory/bench side.  
2. Types of stem cells in cardiovascular research. Preclinical background 
There are several types of stem cells which have been used with the aim of repairing 
damaged myocardium. Broadly speaking, stem cells can be subdivided into two large 
groups: embryonic and adult. 
2.1 Embryonic stem cells 
Embryonic stem cells (ESC) are present in the earliest stage of embryonic development – the 
blastocyst (this is the stage before the embryo is implanted into the uterine wall, one week 
after fertilization). ESC can divide indefinitely in vitro and are pluripotent: they are capable 
of generating any terminally differentiated cell in the human body that is derived from any 
one of the three embryonic germ layers (Perin & Silva 2006). 
Classic experimental studies have demonstrated cardiomyocyte obtention from ESC, with 
the same structural and functional properties as cardiomyocytes present in the cardiac 
muscle (Kehat et al., 2001), and showing even successful electromechanical coupling with 
host myocardium. After their transplantation into the infarcted myocardium, these cells can 
engraft and survive in the myocardial tissue network, providing an improvement in 
ventricular function in several small animal preclinical models (Klug et al., 1996; Min et al., 
2002). On the other hand, in chronic heart failure models, ESC have been proved to 
differentiate into new cardiomyocytes and also into endothelial and smooth muscle cells 
forming new blood vessels (Yamashita et al., 2000). 
Nevertheless, despite the enormous evidence available regarding ESC isolation, growth, 
differentiation and transplantation in animal models, there are several issues that have 
restricted their clinical applications in human RCT in most countries: ethical and legal 
considerations, limited numbers of cell lines, limited resources, the difficulty of obtaining 
autologous ESC, the need for immunosuppression in case of allogenic cells and the potential 
risk for tumorigenesis (Thomson et al., 1998).  
2.2 Adult stem cells 
Adult stem cells are intrinsic to specific tissues of the postnatal organism into which they are 
committed to differentiate. Theoretically, adult stem cells are capable of self-renewal, 
yielding mature differentiated cells which are: 1) integrated into a particular tissue and 2) 
capable of performing the specialized function of that tissue. Adult-tissue specific stem cells 
are present in organs with self-renewal capacity, including the liver, pancreas, skeletal 
muscle, skin and bone marrow. These are the most investigated cells in regenerative 
medicine and include different cellular types: 
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2.2.1 Skeletal myoblasts 
Skeletal myoblasts are satellite cells that remain in a quiescent stage between the basal 
lamina and the sarcolemma on the periphery of mature skeletal muscle fibers. They can be 
obtained from muscular biopsies and easily expanded in vitro (Murry et al., 1996; Taylor et 
al., 1998). This kind of stem cells has received considerable attention in the setting of chronic 
ischemic ventricular dysfunction, because these cells: 1) do not need a specific 
microenvironment to differentiate, 2) can be expanded without problems in undifferentiated 
stages, and 3) are highly resistant to ischemia and can multiply after injury. These cells are 
programmed to differentiate into myogenic lineages and, after their transplantation into 
scarred myocardium, they become myotubes and myocytes with the characteristics and 
function of skeletal muscle (Leobon et al., 2003; Pagani et al., 2003). In other words, 
transdifferentiation into cardiomyocytes, which was their first hoped mechanism of action, 
is an exceptional event rarely seen at the graft-host interface. Therefore, their benefitial effect 
is thought to be mediated through myocyte contraction, paracrine effects and by an increase 
in the infarcted wall resistance and stiffness, thus limiting ventricular dilatation and adverse 
remodeling. Safety concerns include basically the risk of ventricular arrhythmias observed 
in the first clinical trials, due to the absence of electromechanical coupling of the myoblasts 
with another cells or with host myocardium. As a consequence, in most of these protocols 
patients were treated at the same time with prophylactic implantable cardiac defibrillators 
and/or chronic amiodarone. Administration of skeletal myoblasts after certain culture 
conditions (with autologous human serum) could avoid this risk (Herreros et al., 2003).  
2.2.2 Bone marrow-derived cells 
The bone marrow is one of the most investigated sources of adult stem cells. It is a complex 
organ with a specific geometric organization and an intrincate system of cell-to-cell 
interaction and signaling, and it contains several cell subpopulations: 1) differentiated cells 
like stromal supporting mesenchymal cells, vascular cells, adipocytes, osteoblasts and 
osteocytes, and 2) progenitor cells. The most important subpopulation is the bone marrow 
mononuclear cell (BMMC) fraction, that includes mesenchymal stem cells (MSC), 
hematopoietic progenitor cells (HPC) and endothelial progenitor cells (EPC) (Shizuru et al., 
2005; Suva et al., 2004). It also contains more committed cell lineages, such as natural killers, 
T and B lymphocytes. However, after the finding that MSC and EPC represent, respectively, 
only 0.01% and 1-2% of the total amount of cells included in BMMC fraction, culture 
techniques have been developed to select a specific type of cell and to expand it to obtain 
solutions with higher numbers of cells. 
BMMC can be easily harvested, isolated, in vitro expanded and administered to the patient 
with several delivery devices. The plasticity of these cells has been demonstrated in classic 
preclinical studies, showing even transdifferentiation into mature cells from different 
germinal layers.  
It has been observed that BMMC contribute to the formation of new cardiomyocytes and 
endothelial cells in ischemic areas when injected after an AMI in animal models. In treated 
animals, an improvement of hemodynamic parameters was demonstrated (Jackson et al., 
2001; Orlic et al., 2001a).  
Regarding HPC, no real specific surface antigen has been described to identify these cells. 
The antigens CD34, CD133 and CD117 and the surface markers c-kit, Sca-1 and Thy-1 have 
been used to sort this subtype of BMMC. C-kit+ cells without hematopoietic markers (lin-) 
have been administered after AMI, with a noticeable increase in the number of 
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cardiomyocytes in the infarcted area, improvement of the ventricular function and survival 
benefits (Orlic et al., 2001b). However, other researchers have proved differentiation of these 
HPC into hematopoietic lineages and with the same results of reversing adverse remodeling 
and preventing post-infarction ventricular dysfunction (Balsam et al., 2004). Finally, 
improvements of myocardial perfusion, capillary density/collateral vessel formation and 
left ventricular ejection fraction have also been observed in other studies after HPC injection 
in AMI models, with a significant reduction of the infarct size (Kamihata et al., 2001).  
EPC were first defined as cells positive for both hematopoietic stem cell markers such as 
CD34 and endothelial marker proteins such as vascular endothelial growth factor receptor 2 
(VEGFR-2) or CD133. CD133 (also known as prominin or AC133) is expressed on HPC and 
on early stages of EPC, but is absent on mature EPC and monocyte cells. CD133+ cells 
promote angiogenesis in ischemic tissues, differentiating into adult endothelial cells and 
secreting angiogenic factors. The main drawback of CD133+ cells is their low number in the 
BMMC fraction (they represent less than 1% of the total population) and the impossibility of 
in vitro expansion. In fact, cytokine treatment with granulocyte colony-stimulating factor 
(G-CSF) is needed in order to mobilize a sufficient number of cells from the bone marrow 
(Virmani et al., 2006). 
EPC have similar phenotypic and functional characteristics to those shown by fetal 
angioblasts. Indeed, they arise from a common hemangioblast precursor in the adult bone 
marrow (Virmani et al., 2006). Endothelial cell lineage markers used to sort these cells 
include CD34, Flk-1, VE-cadherin, platelet-endothelial cell adhesion molecule 1 (PECAM-
1), von Willebrand factor (vWF) and E-selectin. Conversely to what happens with other 
stem cells, EPC have been proved to transdifferentiate into cardiomyocytes and smooth 
muscle cells in vivo. Besides, they increase capillary density after an AMI by means of 
angiogenesis and arteriogenesis mechanisms, reduce collagen deposits and cardiomyocyte 
apoptosis, and improve cardiac function (Kocher et al., 2001). Again, the ability to expand 
these cells is limited by their scarcity in peripheral blood. Furthermore, functional 
impairment of EPC has been observed in the elderly and in several pathologic conditions 
(i.e., diabetes mellitus). Recently, specific subpopulations of EPC have been described: 
CD14+/CD34- cells, which have shown very high plasticity (Yoon et al., 2005), and 
CD14+/CD34+ cells, which have been demonstrated to induce a paracrine response by 
releasing angiogenic growth factors.  
MSC are one of the most promising types of stem cells for cardiac repair. They have been 
isolated from the bone marrow stroma (although they can also be found around blood 
vessels, in muscle, skin and adipose tissue) and exhibit unique characteristics, such as a 
multipotent differentiaton potential capacity and the lack of surface markers. Indeed, they 
are CD34-, CD45- and CD133- cells that show an immunophenotype positive for adhesion 
proteins like CD29, CD44, CD71, CD90, CD105, CD106, CD117, CD120a, CD124, SH2, SH3 
and SH4 (Pittenger & Martin, 2004). This is the reason why MSC can be isolated after 
density centrifugation by means of their ability to adhere to culture plates. Purified 
human MSC have been shown to migrate and differentiate to a cardiomyocyte phenotype 
and to endothelial cells in both healthy and infarcted myocardium (Toma et al., 2002). In 
the former MSC express cardiac surface markers, and in the latter they improve wall 
motion and prevent the adverse remodeling process. One advantage of MSC is that they 
are considered to be immuneprivileged. Thus, allogenic MSC have been successfully 
transplanted into murine hearts without the need for immunosuppression (Zimmet & 
Hare, 2005).  
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2.2.3 Adipose-derived stem cells 
Recently, it has been shown that, besides committed adipogenic, endothelial and pluripotent 
vascular progenitor cells, the adipose tissue stroma contains multipotent adipose-derived 
stem cells (ADSC) (Sanz-Ruiz et al., 2009). These self-renewal cells possess high potentiality, 
and are capable of differentiating into myogenic, neural and cardiomyocytic lineages, in this 
last case showing even spontaneous beating. The phenotype of ADSC is similar to that of 
MSC (i.e., ADSC also express adhesion molecules in their surface) (Sanz-Ruiz et al., 2008). 
The similarities of both cell types in terms of potentiality and the fact that adipose tissue can 
be easily obtained in large amounts by means of a simple liposuction procedure, have 
pointed at the human adipose tissue as a novel promising alternative source of stem cells for 
cardiovascular repair that has shown encouraging results in the preclinical field (Fraser et 
al., 2004). In fact, in our center two first-in-man phase II randomized trials have been 
conducted with ADSC: with intracoronary administration after an AMI (APOLLO trial) and 
with transendocardial injection in “no-option” patients with advanced CAD (PRECISE trial).  
2.2.4 Resident cardiac stem cells 
A newly discovered population of resident cardiac stem cells (CSC) has been recently 
identified in the adult heart, which contributes to myocardial regeneration in animal models 
of AMI (Beltrami et al., 2003; Oh et al., 2003; Urbanek et al., 2003; Urbanek et al., 2005). These 
cells express surface markers such as c-kit, Sca-1 and Abcg2. However, the phenotypic 
characterization of this lineage is not definitely clear. Indeed, currently all CSC types are 
thought to be distinct from each other. In the adult human heart, these clusters of CSC have 
shown their capacity to differentiate into cardiomyocytes, to fuse with pre-existing 
cardiomyocytes and to differentiate also into smooth muscle and endothelial cells, 
providing both myocardial and vascular regeneration. A novel cardiac cell type has been 
identified using the transcription factor islet-1 (isl1). These isl1+ cells have been proposed 
even for pacemaker cell and conduction system repair (Laugwitz et al., 2005). Finally, CSC 
have been isolated and expanded for the first time from human myocardial biopsies, 
offering another new source of stem cells in cardiovascular regenerative medicine (Messina 
et al., 2004).  
2.2.5 Cord-blood derived stem cells 
The umbilical cord blood contains a high proportion of hematopoietic and mesenchymal 
stem cells, and in higher numbers than in peripheral blood or in the bone marrow. Also 
known as “somatic non-restricted stem cells”, these cells are negative for c-kit, CD34 and 
CD45, and can differentiate into cardiomyocytes. They have been administered after an AMI 
in animal models, improving ventricular perfusion and contractility, and reducing the 
infarct size (Ma et al., 2005). Nevertheless, cord-blood stem cells have not been used in 
clinical trials so far. 
2.3 Induced or “embryonic-like” stem cells 
At the end of 2007, two groups reported for the first time the generation of pluripotent stem 
cell lines derived from adult human cells (Takahashi et al., 2007; Yu et al., 2007). 
Differentiated adult somatic human cells were successfully reprogrammed into a 
pluripotent state by transduction of four defined transcription factors. The resulting 
induced-pluripotent stem cells (iPS) were proved to have the same morphological 
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characteristics, surface markers, proliferative capacity and potentiality as those known in 
ESC. In the first study (Takahashi et al., 2007), the factors Oct3/4, Sox2, Klf4 and c-Myc were 
transduced in human dermal fibroblasts, and in the second one (Yu et al., 2007), Oct4, Sox2, 
NANOG and LIN28 were induced in the same type of adult cells. These iPS can differentiate 
into any kind of cell from any of the three embryonic germ layers, but two safety concerns 
have arisen: 1) the risk of mutations after viral transfection, and 2) the risk of teratoma 
formation. In other words, although these studies have meant a revolution in the field of 
regenerative medicine, we still have a long way to cover before their application in human 
pathology. 
3. Host tissue and cell related issues. Understanding the ischemic 
myocardium 
The two main determiners of cardiovascular repair are stem cells and injured myocardial 
tissue in which these cells are delivered. Both play the central role that will establish the 
efficacy of the treatment, and knowledge of the molecular/cellular changes and interactions 
between them is crucial when designing new RCT.  
After AMI, if blood flow is not restored quickly, cell death and myocardial necrosis are 
definitive. This activates a complement cascade with free radical and cytokine generation 
that recruit leukocytes and initiate the inflammatory response. Inflammation, while 
potentially detrimental to surviving cardiomyocytes, is necessary to clear away the debris 
(clearance of necrotic cells) and orchestrate downstream healing events. Chronic 
inflammatory cells such as macrophages and mast cells secrete cytokines and growth 
factors, which in turn activate fibroblasts to proliferate and synthesize collagen, a major 
component of the scar that replaces cardiomyocyte loss. Neovascularization is also 
stimulated by the release of growth factors from the inflammatory cells. Scar remodeling 
may continue for months to years, depending on the extent of the initial ischemic event 
(Lindsey et al., 2003).  
Left ventricle (LV) remodeling, defined as post-AMI changes in wall structure, chamber 
geometry and pump function, is mainly caused by changes in extracellular matrix (ECM). 
Cardiac ECM not only supports and aligns cardiomyocytes, thereby preserving a 
fundamental mechanical relationship by which sarcomeric shortening is translated to 
muscle force contraction, but also has signaling functions. Indeed, ECM is a storage depot 
for growth factors, hormones and cytokines, and uses integrins to communicate with cells 
(Lindsey et al., 2003). All these functions are lost after myocardial ischemia due to the 
release from inflammatory and endogenous cells of matrix metalloproteinases (MMP) and 
cytokines. MMP degrade ECM, disengage integrins and stimulate reparative fibrosis. 
Cytokines like tumor necrosis factor α (TNF-α) and interleukins like IL-1 and IL-6 induce 
MMP synthesis and are related to the development of LV dysfunction, pulmonary edema, 
endothelial dysfunction and cardiomyocyte apoptosis (Dewald et al., 2004).  
These cellular and signaling processes that constitute the proliferative phase of infarct 
healing in the myocardium influence and determine the fate of implanted stem cells. 
Ischemic myocardium constitutes an inflammatory hostile environment for stem cells, 
which is devoid of nutrients and oxygen and lacks survival signals from the ECM and cell-
to-cell interactions. Indeed, only a small fraction of them survive in such adverse conditions. 
Nevertheless, some studies have shown that certain implanted stem cells may improve or 
counteract this situation. Intramyocardial transplantation of EPC after AMI induces 
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significant and sustained increase in angiogenic, antiapoptotic and chemoattractant factors, 
that are up-regulated in both transplanted and host cells (i.e., vascular endothelial growth 
factor-A [VEGF-A], fibroblast growth factor-2 [FGF-2], angiopoietin-1 [Ang-1], angiopoietin-
2 [Ang-2], placenta growth factor [PIGF], hepatocyte growth factor [HGF], insulin-like 
growth factor-1 [IGF-1], platelet-derived growth factor-B [PDGF-B] and stromal cell-derived 
factor-1 [SDF-1]) (Cho et al., 2007). These humoral factors provide an additional favorable 
milieu for neovascularization and repair or regeneration of ischemic myocardium. 
Furthermore, there is a cross-talk between the heart and the bone marrow mediated by 
humoral effects that may improve this therapeutic effect: it has been proved that EPC 
transplantation further mobilizes endogenous BMMC into peripheral circulation, recruiting 
them into the ischemic myocardium (Cho et al., 2007). 
Having these considerations in mind, new lines of research are being developed to improve 
cell survival rates in the ischemic myocardium, between them (Wollert & Drexler 2010): 
1. Preconditioning of the myocardium to retain a higher number of cells: low-energy 
shock waves, ultrasound-mediated destruction of microbubbles in the coronary 
circulation and extracorporeal shock wave treatment have proved to increase retention 
of EPC, BMMC and MSC. 
2. Activation or increase of chemotactic factors to attract cells to the damaged area: high 
mobility group box-1 (HMGB-1), SDF-1 or its receptor CXCR4, β2 integrin and 
endothelial nitric oxide synthase can be activated to increase the rate of homing of 
different types of stem cells (i.e., progenitor blood cells, EPC).      
Regarding stem cells administered to the myocardium, their functional activity is 
determined by age and cardiovascular risk factors. As a consequence, future phase II-III 
RCT will explore cell enhancement strategies intended to increase their therapeutic 
potential. Several strategies are currently under investigation (Wollert & Drexler 2010): 
1. Pretreatment of the patients with drugs to stimulate cell potenciality: statins, 
rosiglitazone and nitric oxide synthase enhancer AVE9488 can improve the migratory, 
invasive and neovascularization capacity of EPC. 
2. Strategies to prolong cell survival: between them, the use of a combination of growth 
factors to stimulate the expression of cardiomyocyte genes in MSC, the use of heat 
shock to increase the resistance of cells to external stressors and the pretreatment of 
ESC-derived cardiomyocytes with heat shock and a cocktail of survival factors, are 
being explored. 
3. Genetic modification of the cells prior to administration: overexpression of 
antiapoptotic genes or genetic manipulation to maintain cell´s functionality (i.e., 
capacity to secrete paracrine mediators, to connect with host myocardium or to 
differentiate into specialized cardiac cell types) can be achieved through genetic cell 
engineering. 
4. Combined injection of cells and biomaterials: BMMC encapsulation within scaffolds 
(epicardial patches) or peptide nanofibers represents another strategy that needs further 
investigation. 
4. Patient selection and delivery methods 
Patients with larger AMI or with severely depressed baseline left ventricular ejection 
fraction (LVEF) and stroke volumes, or those with transmural extent of the infarct seem to 
benefit the most after BMMC treatment (Wollert & Drexler 2010). Conversely, patients with 
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microvascular obstruction may not respond to intracoronary infusion of cells. Therefore, 
patient selection before conducting a RCT must take into account the pathophysiologic basis 
of the disease and baseline characteristics of the patients. For instance, it is well known that 
age, cardiovascular risk factors and previous heart failure have a negative impact on the 
potentiality and functional capacity of most types of stem cells in cardiovascular research. 
On the other hand, exploration of new delivery methods is mandatory, due to the low rate 
of cell retention, engraftment and survival in the myocardium with the present routes of 
administration. New devices include transcoronary arterial injection into the perivascular 
space, improvements in transendocardial injection needle design and the fusion of different 
imaging techniques for a more precise delivery (i.e., X-ray/MRI suites used in conjunction 
with electroanatomic maps of the LV). 
5. Mechanisms of action 
Nowadays, it is believed that stem cell therapy could lead to successful cardiac regeneration 
or repair by any or a combination of three main general mechanisms (figure 1): 1) 
differentiation of the administered cells into all of the cellular constituents of the heart (i.e., 
cardiomyogenesis and vasculogenesis processes), or, less probably, fusion of the 
administered cells with those, 2) release of factors capable of paracrine signaling from the 
administered cells and 3) stimulation of endogenous repair by injected cells, through stem 
cell cardiac niches activation (Mazhari & Hare, 2007). 
 
Fig. 1. Proposed mechanisms of stem cell function after homing into the damaged heart. 
Note that differentiation processes and paracrine effects activate a cascade of events that 
interact actively to create new blood vessels and cardiomyocytes, with the final objective of 
functional cardiac repair. CSCs: cardiac stem cells. 
5.1 Cardiomyogenesis and vasculogenesis. 
While in the classic studies of the beginning of the decade (trans)differentiation of BMMC 
into cardiomyocytes, smooth muscle cells and endothelial cells was postulated as the main 
mechanism that might explain the cardiac recovery resulting from stem cell therapy, this 
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phenomenon has been demonstrated in low proportions in more recent studies. Regarding 
cellular fusion of administered cells with host myocardial ones, to date there is little 
evidence to support this hypothesis.   
5.2 Paracrine actions 
Given that differentiation debate is still ongoing and that the number of newly generated 
cardiomyocytes and blood vessels is too low to explain significant functional improvements, 
the paracrine hypothesis is now considered the most plausible. According to this idea, the 
functional benefits of stem cells might be related to secretion of soluble factors that, acting in 
a paracrine fashion, protect the heart, attenuate pathological LV remodeling, induce 
neovascularization and promote regeneration (Gnecchi et al., 2008). BMMC and MSC have 
been extensively studied and proved to produce and secrete a broad variety of cytokines, 
chemokines and growth factors, between them VEGF, FGF, HGF, IGF, adrenomedullin, 
thymosin β4 (TB4), SDF-1, PDGF and angiopoietin. These paracrine mediators are 
expressed/released in a temporal and spatial manner exerting different effects depending 
on the microenvironment after injury. In addition, these released factors may have autocrine 
actions on the biology of stem cells themselves (Gnecchi et al., 2008). 
The paracrine factors may influence adjacent cells and exert their actions via several 
mechanisms, including:  
1. Myocardial protection: MSC and BMMC in an ischemic environment release 
cytoprotective molecules that increase cardiomyocyte survival (VEGF, FGF, HGF, IGF-
1, TB4, SDF-1, PDGF and IL-1). 
2. Neovascularization: BMMC, MSC and EPC can give rise to vascular structures. The 
molecular processes leading to angiogenesis and arteriogenesis involve mediators such 
as nitric oxide, VEGF, SDF-1, FGF, HGF and angiopoietin. 
3. Cardiac remodeling: paracrine factors released by transplanted stem cells may alter the 
ECM (i.e., inhibiting cardiac fibroblast proliferation and types I and III collagen 
synthesis), resulting in more favorable post-AMI remodeling and strengthening of the 
infarct scar. Stem cells (MSC) may also produce molecules that limit local inflammation, 
thus reducing the remodeling process. 
4. Cardiac contractility and metabolism: it has been demonstrated that stem cell therapy 
limits infarct size and prevents LV dysfunction. On the other hand, MSC and BMMC 
secrete inotropic factors (i.e., IGF-1) that positively modulate cell contractility, and these 
cells attenuate the profound bioenergetic abnormalities found in the border zone of 
myocardial infarction. 
5. Cardiac regeneration: differentiation and cell fusion with native cardiomyocytes occur 
in very low rates after stem cell administration. Therefore, it is now believed that 
exogenous stem cell transplantation may activate resident CSC and/or stimulate 
cardiomyocyte replication via paracrine action. Factors secreted by BMMC, MSC and 
EPC, including HGF, SDF-1, VEGF and IGF-1, enhance proliferation, mobilization, 
differentiation, survival and function of CSC or even restoration of cardiac stem cell 
niches. 
5.3 Endogenous repair 
As we have seen, clonogenic and self-replicating endogenous CSC have been isolated and 
cultured from human hearts. These CSC – located in cardiac stem cell niches – have the 
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capacity to differentiate into endothelial cells, smooth muscle myocytes and cardiomyocytes. 
Though insufficient for a complete repair of the myocardium after any kind of insult, these 
cells can be activated by extracardiac delivered cells. Thus, administered allogeneic MSC 
participate in maintaining stem cell niches, and through cell-to-cell interactions – apart from 
paracrine effects – may not only restore lost cellular constituents (differentiation) but also 
these niches with an ongoing and regulated self-replicating capacity (Mazhari & Hare, 2007). 
6. Clinical scenarios in stem cell therapy. Evidence available 
Stem cell therapy has accumulated growing evidence in different pathophysiological 
conditions in small and large animal models, but human research has been almost limited to 
CAD. In this chapter we will focus on the largest and most relevant randomized placebo-
controlled clinical trials in humans (tables 1 through 4). 
Natural history of CAD can be divided into acute (AMI) and chronic phases (chronic 
ischemic heart disease). In the latter stem cell therapy has been investigated in the subset of 
1) ischemic heart failure (ventricular dysfunction) and 2) chronic myocardial ischemia 
(refractory angina). 
In patients where restoration of contractile function is the clinical goal – such as those with 
end-stage ischemic heart failure or those early post-infarction – delivering cells with 
contractile potential may be of high priority. Under these conditions, naturally myogenic 
cells (i.e., skeletal myoblasts, cardiomyocytes or any progenitor cell driven down a muscle 
lineage) appear to be the first choice. However, on the one hand, formation of new 
myocardial mass has only been strictly established for ESC, and is a process that has been 
achieved in very few trials and in small percentages with adult stem cells. And on the other 
hand, most of the studies after AMI have used BMMC as an easily accessible source of adult 
stem and progenitor cells. 
In conditions where chronic ischemia prevails, the angiogenic potential of the cells seems a 
more reasonable approach. In this case, BMMC, EPC, vascular progenitor cells or blood-
derived multipotent adult progenitor cells and MSC may be better choices than myogenic 
precursors. 
6.1 Stem cell therapy after acute myocardial infarction 
Several trials have evaluated stem cell therapy after AMI, some with positive results and 
some with neutral ones. All of them used the intracoronary route, once the patency of the 
infarct-related artery was restored, and most of them with the mononuclear fraction of the 
bone marrow (table 1). Four main RCT have been published with positive findings so far. In 
the BOOST trial (Wollert et al., 2004), BMMC were proved to improve left ventricular 
contractility in the infarct border zone and global LVEF by 6%. However, only patients with 
larger infarcts showed maintained benefits in terms of LVEF at long follow-up (18 months). 
In the REPAIR-AMI trial (Schachinger et al., 2006), infusion of BMMC promoted an increase 
in LVEF of 2.8% at 12 months. The FINCELL trial (Huikuri et al., 2008) reported an 
improvement of 5% in LVEF after BMMC delivery. Finally, in the REGENT trial (Tendera et 
al., 2009), patients treated with BMMC and with CXCR4+/CD34+ BMMC showed an 
increase of 3% in LVEF which was not observed in the control group, but these differences 
were not significant between treated and control patients at 6-months follow-up. This trial 
was limited by imbalances in baseline LVEF and by incomplete follow-up. 
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Trial (year) n Cell type 
Cell 
count 
Days 
after 
AMI
Primary 
endpoint 
(follow-up) 
Comments 
Chen (2004) 69 MSC 9 x 109 18 Improved LVEF 
at 6m 
LVEF by 
echocardiography 
BOOST 
(2004) 
60 BMMC  2 x 109 6±1 Improved LVEF 
at 6m 
Effect diminished 
after 18/61m 
REPAIR-
AMI (2006) 
187 BMMC  2 x 108 3-6 Improved LVEF 
at 4m 
LVEF by 
ventriculography 
Janssens 
(2006) 
66 BMMC  2 x 108 1 No change LVEF 
at 4m 
Improved regional 
contractility and 
reduction in 
infarct size 
ASTAMI 
(2006) 
97 BMMC  7 x 107 6±1 No change LVEF 
at 6m 
LVEF ↑8% by 
SPECT,↑1% by 
MRI 
TCT-STAMI 
(2006) 
20 BMMC 4 x 107 1 Improved LVEF 
at 6m 
LVEF by 
echocardiography 
FINCELL 
(2008) 
77 BMMC  4 x 108 3 Improved LVEF 
at 6m 
LVEF by 
ventriculography 
Meluzin 
(2006) 
66 BMMC 1 x 107 
(low d) 
1 x 108 
(high d) 
7 Improved LVEF 
at 3m in high 
dose group 
LVEF by SPECT 
Penicka 
(2007) 
27 BMMC 3 x 109 9 No change LVEF 
at 4m 
LVEF by 
echocardiography 
HEBE (2008) 189 BMMC vs PBC  - 3-8 No changes in 
global or 
regional LV 
function 
Final results 
pending 
REGENT 
(2009) 
117 BMMC 
(unselected, 
CD34+/CXCR4+)
2 x 108 
(unsel), 
2 x 106  
(CD34+) 
3-12 Improved LVEF 
with both cell 
types 
LVEF by MRI (in 
117/200 patients) 
MSC: mesenchymal stem cells (bone marrow origin); BMMC: bone marrow mononuclear cells; PBC: 
peripheral blood cells; LVEF: left ventricular ejection fraction; LV: left ventricle; SPECT: single-photon 
emission computed tomography; MRI: magnetic resonance imaging. 
Table 1. Randomized clinical trials with stem cells in patients with acute myocardial 
infarction (intracoronary delivery). 
On the other hand, three RCT resulted in neutral findings. Janssens et al. (Janssens et al., 
2006) reported no changes in LVEF after BMMC infusion, but a reduction in the infarct 
volume and an improvement in regional contractility in the greatest transmural infarct cases 
were observed in treated patients. In the ASTAMI trial (Lunde et al., 2006) no significant 
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effects on LVEF, LV volumes, or infarct size were observed after BMMC administration. The 
smaller number of cells and differences in the cell isolation protocol were invocated to 
explain these findings. Finally, in the HEBE trial (van der Laan et al., 2008), presented at the 
AHA Scientific Sessions in 2008, no changes in global or regional LV systolic function were 
reported after BMMC and mononuclear cells isolated from peripheral blood injection.   
So far, no safety concerns after BMMC intracoronary infusion have emerged. The risk of a 
higher rate of instent restenosis was not confirmed in the FINCELL trial (Huikuri et al., 
2008) and in two recent meta-analyses (Lipinski et al., 2007; Martin-Redon et al., 2008). 
Moreover, none of the trials reported an increased incidence of malignant arrhythmias with 
BMMC (Wollert & Drexler, 2010). 
Two trials have used MSC after AMI. The study by Chen et al. (Chen et al., 2004) 
demonstrated an improvement in LVEF and perfusion with intracoronary infusion of these 
cells, but these results have not been duplicated. Hare et al. (Hare et al., 2009) intravenously 
administered allogeneic MSC after an AMI with no higher rate of MACE and some benefits 
in terms of LVEF. 
New types of cells are also being explored, like ADSC (figure 2). No evidence is available to 
date, but the first-in-man RCT with intracoronary administration of freshly isolated ADSC 
after AMI (the APOLLO trial) has been recently completed.  
 
 
Fig. 2. Autologous adipose-derived mesenchymal stem cells during mitosis (left pannel) and 
growing in colonies in the 6th day of culture (magnification x 10, right pannel). These cells 
were expanded from the adipose tissue stroma-vascular fraction under good manufacturing 
practice (GMP) conditions in our Cell Production Unit (Hospital Gregorio Marañón, 
Madrid). 
Another approach for stem cell therapy after AMI is cell mobilization from the bone marrow 
with the administration of G-CSF. Several RCT have been published, but results have been 
somehow less encouraging (table 2). Only three trials have reported positive results. In the 
FIRSTLINE-AMI trial (Ince et al., 2005), the RIGENERA study (Leone et al., 2007) and in the 
study by Takano et al. (Takano et al., 2007), significant improvements in LVEF were 
observed. The rest of the trials showed negative findings. 
Finally, the MAGIC trials used a combination of G-CSF and intracoronary injection of 
peripheral blood progenitor cells. In the first trial no differences in LVEF were noted, and an 
increase in instent restenosis rate was observed (G-CSF administration before bare-metal 
stent implantation) (Kang et al., 2004). Then the investigators changed the design and used 
drug-eluting stents. In the MAGIC 3-DES trial, positive results in terms of LVEF were found 
after mobilization and intracoronary injection of isolated cells (Kang et al., 2006). 
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Trial (year) n Dose 
Timing 
after AMI
Follow-up Comments 
Valgimigli 
(2005) 
20 5 µg/kg x 4 d 1 d No change LVEF 
at 6m 
LVEF by SPECT 
FIRSTLINE
-AMI (2005) 
50 10 µg/kg x 6 d 90 min Improved LVEF 
at 4m 
LVEF by 
echocardiography 
REVIVAL-2 
(2006) 
114 10 µg/kg x 5 d 5 d No change LVEF 
at 5m 
LVEF by MRI 
STEMMI 
(2006) 
78 10 µg/kg x 6 d 28 h No change LVEF 
at 6m 
LVEF by 
echocardiography 
and MRI 
G-CSF-
STEMI 
(2006) 
44 10 µg/kg x 5 d 35 h No change LVEF 
at 3m 
LVEF by MRI 
Ellis (2006) 18 5µg/kgx5d 
(low d), 
10µg/kgx5d 
(high d) 
< 30 h Improved LVEF 
at 30d 
LVEF by 
echocardiography 
RIGENERA 
(2007) 
41 10 µg/kg x 5 d 5 d Improved LVEF 
at 6m 
LVEF by 
echocardiography 
Takano 
(2007) 
40 2,5 µg/kg x 5 d 1 d Improved LVEF 
at 6m 
LVEF by SPECT 
MAGIC 
(2004)* 
27 10 µg/kg x 4 d; 
PBC: 1 x 109 
1 d No change LVEF 
at 6m 
LVEF by SPECT 
MAGIC 3-
DES (2006)* 
50 10 µg/kg x 3 d; 
PBC: 2 x 109 
1 d Improved LVEF 
at 6m 
LVEF by MRI 
Table 2. Randomized clinical trials with granulocyte colony-stimulating factor in patients 
with acute myocardial infarction (subcutaneous). *: MAGIC trials used a combination of 
indirect mobilization (G-CSF) and direct intracoronary injection of peripheral blood cells 
(PBC); LVEF: left ventricular ejection fraction; SPECT: single-photon emission computed 
tomography; MRI: magnetic resonance imaging. 
6.2 Stem cell therapy for chronic ischemic heart disease 
6.2.1 Ischemic heart failure 
Skeletal myoblasts and BMMC have been used in heart failure patients (table 3). The MAGIC 
trial (Menasche et al., 2008), with transepicardial injection of skeletal myoblasts during 
coronary artery bypass graft surgery, reported no changes in global or regional contractility. 
However, a reduction in LV end-diastolic and end-systolic volumes was observed in the high-
dose group. Moreover, a trend towards a higher incidence of ventricular arrhythmias was 
noted. Dib et al.(Dib et al., 2005) reported an improvement in LVEF and viability after 
myoblasts transendocardial injection, in contradiction with the SEISMIC trial (presented by 
Serruys at the 2008 ACC meeting) which showed no benefit of the same procedure at 6 
months.  
In the TOPCARE-CHD trial (Assmus et al., 2006), BMMC intracoronary delivery into the 
coronary artery supplying the most dyskinetic LV area showed an increase in LVEF of 2.9%, 
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whereas progenitor circulating cells infusion and controls did not show any positive change. 
No major adverse cardiac events (MACE) were reported in this trial. Another trial has been 
recently published with BMMC by the group of Strauer (the STAR-heart study) (Strauer et 
al., 2010). Although it lacks of a randomized design, this study represents the largest trial 
with BMMC in patients with severe LV dysfunction. Intracoronary transplantation 
improved haemodynamics at rest (including LVEF), exercise capacity, LV contractility and 
geometry (decrease in LV end-diastolic and end-systolic volumes, decrease in infarct size), 
and a remarkable reduction in mortality at 5-years follow-up was observed. 
 
Trial n Cell type Delivery Timing Primary 
endpoint 
Comments 
MAGIC 97 SM  epi  >4 weeks No change 
LVEF 
Reduction in 
LVEDV/LVESV 
Dib 23 SM endo >10 years Improved LVEF 
and viability 
- 
SEISMIC 47 SM endo chronic No change 
LVEF 
 
TOPCARE-
CHD 
58 BMMC vs 
CPC 
ic 81±72 
months 
Improved LVEF 
w/BMMC 
- 
STAR 391 BMMC vs 
controls 
ic 8.5±3.2 
years 
Improved 
LVEF, 
LVEDV/LVESV
, exercise 
capacity  
No randomized 
design. 
Reduction of 
infarct size and 
mortality 
Table 3. Randomized clinical trials in patients with chronic ischemic heart failure. SM: 
skeletal myoblasts; BMMC: bone marrow mononuclear cells; CPC: circulating progenitor 
cells; epi: transepicardial; endo: transendocardial; ic: intracoronary; LVEF: left ventricular 
ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-
systolic volume. 
6.2.2 Chronic myocardial ischemia 
Patients with advanced CAD and no further options of revascularization (“no-option” 
patients) have also been studied in stem cell therapy trials (table 4). Three RCT have been 
completed using the transendocardial route after electromechanical mapping of the LV, 
with BMMC or blood-derived progenitor cells. Losordo et al. (Losordo et al., 2007) studied 
peripheral CD34+ cells isolated after G-CSF injections. Angina frequency and exercise time 
were improved, but no clear effects on myocardial perfusion were observed. In the 
PROTECT-CAD trial (Tse et al., 2007), BMMC injections improved NYHA functional class, 
exercise time, LVEF, wall thickening and stress-induced perfusion defects. Finally, Van 
Ramshorst et al. (van Ramshorst et al., 2009) reported better LVEF, myocardial perfusion, 
angina functional class, exercise capacity and quality of life after BMMC administration.  
ADSC have also been studied in this type of patients. The PRECISE trial is a prospective, 
double blind, RCT that has randomised 27 patients with end-stage CAD not amenable for 
revascularization and with moderate-severe LV dysfunction to receive freshly isolated 
ADSC or placebo in a 3:1 ratio. The cells were delivered via transendocardial injections after 
www.intechopen.com
Randomized Clinical Trials in Stem Cell Therapy  
for the Heart - Old and New Types of Cells for Cardiovascular Repair 
 
273 
LV electromechanical mapping with the NOGA XPTM delivery system (BDS, Cordis 
Corporation, Johnson and Johnson) (figure 3), and results are still waiting for publication. 
 
Trial n Cell type Delivery Timing Primary 
endpoint 
Comments 
Losordo 24 CD34+ endo chronic Improved 
angina 
parameters 
No clear perfusion 
benefit 
PROTECT-
CAD 
28 BMMC endo chronic Improved 
angina 
parameters 
Improved LVEF 
and perfusion 
Van 
Ramshorst 
50 BMMC endo chronic Improved 
angina 
parameters 
Improved LVEF 
and perfusion 
Table 4. Randomized clinical trials in patients with chronic myocardial ischemia. BMMC: bone 
marrow mononuclear cells; endo: transendocardial; LVEF: left ventricular ejection fraction. 
 
 
Fig. 3. Electromechanical mapping of the left ventricle with the NOGA XP™ System (BDS, 
Cordis Corporation, Johnson and Johnson) from a patient enrolled in the PRECISE trial in 
our centre. Myocardial areas with low contractility (red means most akinetic areas) and 
impaired endocardial voltage (red means necrotic myocardium, green hibernating tissue) 
are identified as viable and targeted for cell injection (brown dots).  
7. Safety concerns of stem cell therapy 
As a novel therapy, stem cell therapy has raised several safety concerns, which are listed 
below: 
1. Arrhythmias: malignant arrhythmias can be induced 1) because transplanted cells do 
not engraft in a physiologic electromechanical way, forming functionally isolated 
clusters of cells, 2) because of intrinsic arrhythmogenicity of cells, 3) because 
reinervation of the myocardium, 4) due to local damage or edema after cell injection or 
5) because of the use of heterologous proteins in cell cultures. Ventricular arrhythmias 
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have been reported specifically with skeletal myoblasts (Menasche et al., 2003; Siminiak 
et al., 2004; Dib N 2005) and with CD133+ cells (Bartunek et al., 2005), but without 
compromising the overall safety of this therapy. 
2. Restenosis: the only study that reported a higher incidence of restenosis used G-CSF 
four days before stent implantation (Kang et al., 2004), which was considered to be a 
non-adequate methodology. This risk has not been observed in further trials. 
3. Extracardiac engraftment: administered stem cells are located in the heart in low 
proportions, whereas kidneys, lungs and spleen receive the most of the cells. Local 
intramyocardial injections achieve higher retention rates in the heart. Nevertheless, 
clinical consequences of extracardiac engraftment are so far unknown or even benefitial. 
4. Accelerated atherogenesis: some studies have shown a high proportion of de novo 
lesions in non-treated coronary arteries (Bartunek et al., 2005), but this issue needs 
further evaluation. 
5. Microvascular obstruction: MSC have been proved to cause microinfarctions in canine 
models, but these findings have not been reproduced in human trials (Chen et al., 2004). 
6. Oncogenicity: plutipotent and ESC have the risk of inducing cardiac tumors, but this 
risk is reduced if cells are in culture for no more than 6 or 8 weeks.  
8. The consensus of the task force of the European society of cardiology for 
future trials 
The Task Force of the European Society of Cardiology on stem cells and repair of the heart 
was created in 2006 to investigate and regulate the role of progenitor/stem cell therapy in 
the treatment of cardiovascular disease. It was almost four years ago that this group of 
experts and opinion leaders stated the type of studies needed (Bartunek et al., 2006): 
1. Further large, double-blind, controlled RCT for the use of autologous BMMC in the 
treatment of AMI. The patient population should be all those presenting within 12 h of 
AMI and treated with immediate revascularization, be it primary angioplasty or 
fibrinolysis. 
2. Double-blind, controlled RCT for the use of autologous BMMC in the treatment of AMI 
in those patients presenting late (>12 h) or who fail to respond to therapy (candidates 
for ‘rescue’ angioplasty). Although these groups may represent a small proportion of all 
patients with AMI, their prognosis remains poor. 
3. Double-blind, controlled RCT for the use of autologous BMMC or skeletal myoblasts in 
the treatment of ischemic heart failure. At some stage, the role of autologous 
stem/progenitor cells in the treatment of cardiomyopathies (in particular, dilated 
cardiomyopathy) will need to be examined. 
4. A series of well-designed small studies to address safety or mechanism to test specific 
hypotheses (i.e., studies with labelled cells or to investigate paracrine or autocrine 
mechanisms). Such hypotheses would have arisen from basic science experiments. 
5. Studies to confirm the risk/benefit ratio of the use of cytokines alone (i.e., G-CSF) or in 
conjunction with stem/progenitor cell therapy. 
This Task Force also underlined the necessity for studies with hard clinical endpoints, 
MACE, subjective benefit and economic gain (Bartunek et al., 2006). Another key point is 
standardization, both in outcome measures and in the processing of cells (better achieved in 
specialized centers following GMP routines), in order to derive meaningful comparisons. 
Since these trials will need to include thousands of patients, they should be multicentre and 
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ideally pan-European. On the other hand, the Task Force stated that small uncontrolled 
trials with BMMC should be avoided, as they are unlikely to add anything new to the field. 
9. Next directions in stem cell therapy research.  
Finally, next directions of cardiac cell therapy include: 
1. The study of the array of bioactive molecules that are secreted by stem cells, which have 
been demonstrated to induce neovascularization, modulate inflammation, fibrogenesis, 
cardiac metabolism and contractility, increase cardiomyocyte proliferation and activate 
resident stem cells. The exhaustive analysis of this “secretomes” of BMMC, MSC or EPC 
would lead to a better understating of the mechanisms of action of the cells and to a 
hypothetical protein-based therapy (off-the-shelf, noninvasive, systemic and repetitive 
administration).  
2. The use of different sources of pluripotent stem cells, like ESC, spermatogonial stem 
cells and oocytes. A new era has been initiated with the possibility of reprogramming 
adult cells (skin fibroblasts) to a pluripotent state by retroviral transduction (iPS) 
(Takahashi et al., 2007; Yu et al., 2007). New retroviral vectors and even nonviral vectors 
have been developed to reduce the risk of mutagenesis, and genetic modification of 
cells with suicide genes have been proposed to reduce the risk of tumor formation. 
3. The creation of bioartificial hearts after a process of decelularization with detergents, 
obtention of the underlying extracellular matrix (cardiac architecture) and stem cell 
repopulation (Ott et al., 2008). The “acellular” heart can then be reseeded with cardiac 
stem cells or EPC, showing contractile activity in animal models. This new approach of 
tissue bioengineering has opened a fascinating era in cardiovascular medicine. 
10. Conclusion 
Although mixed results have emerged from the first stem cell therapy RCT in 
cardiovascular medicine, the overall data suggest that these procedures are feasible and safe 
in both acute and chronic scenarios of ischemic heart disease. After phase I-II RCT, it is clear 
that BMMC transfer after AMI has the potential to improve the recovery of LV systolic 
function beyond what can be achieved by current interventional and medical therapies. In 
chronic ischemic heart disease, skeletal myoblasts and BMMC have proved to improve 
myocardial perfusion and contractile performance. 
New types of cells (including ADSC and iPS), improvements in delivery and imaging 
methods, strategies to enhance cell potentiality or to improve the myocardial pro-
inflammatory microenvironment, and the creation of bioartificial hearts are the main new 
directions of research in the near future. Finally, large-scale, phase III, double-blind, 
controlled RCT performed under rigorous safety standards are being initiated to prove 
unequivocal clinical benefits, including improved survival. These trials will definitively 
establish the effectiveness of stem cell therapy in improving clinical outcomes, confirming 
the real potential of cardiac regenerative therapy. 
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